ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gastrointestinal Cancers: Colorectal Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1640646
This article is part of the Research TopicEmerging Trends in Cancer Research: Diagnostic and Therapeutic BreakthroughsView all 7 articles
Clinical value of cystatin S in patients with colorectal cancer chemotherapy
Provisionally accepted
- 1The Fourth Affiliated Hospital of Anhui Medical University, Hefei, China
- 2Anqing First People’s Hospital of Anhui Medical University, Anqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To evaluate the diagnostic utility of serum cystatin S (CST4) in chemotherapy-treated colorectal cancer (CRC) patients and establish its complementary value to conventional tumor markers. Methods: This retrospective cohort study analyzed 81 CRC patients receiving chemotherapy and 83 colorectal polyp controls. Serum CST4 levels were quantified by ELISA alongside six conventional tumor markers (CEA, CA125, CA153, CA199, AFP, CA724). Diagnostic performance was assessed through ROC analysis and multivariate logistic regression. Additionally, in vitro experiments with HCT116 CRC cells were conducted to validate the regulatory relationship between CST4 and PDGFRB. Results: CRC patients exhibited significantly elevated CST4 levels compared to polyp controls (median [IQR]: 54.07 [32.18-91.49] vs 37.48 [24.18-49.28] U/mL, P<0.05). CST4 demonstrated superior diagnostic performance with AUC=0.689 (95%CI:0.607-0.771), outperforming individual conventional markers. Notably, CST4 maintained diagnostic independence across tumor stages (P>0.05) and age groups. A multimodal diagnostic model combining CST4 with CEA, CA724, and CA125 significantly enhanced detection capability (AUC=0.828, sensitivity 74.1%, specificity 81.9%), representing a 28.4% sensitivity improvement over CST4 alone. In vitro, CST4 knockdown in HCT116 cells led to a 68.3% reduction in PDGFRB expression (P<0.0001), validating a regulatory axis between CST4 and PDGFRB. Conclusion: CST4 emerges as a stable post-chemotherapy biomarker that effectively discriminates malignant colorectal lesions. Its integration with conventional markers creates a robust diagnostic algorithm, while functional validation supports a mechanistic role via PDGFRB-mediated pathways. These findings position CST4 as a promising candidate for therapeutic monitoring and recurrence detection in CRC management.
Keywords: Cystatin S, colorectal cancer, biomarker, Pathology, Health
Received: 19 Jun 2025; Accepted: 02 Sep 2025.
Copyright: © 2025 Han, Deng, Xia, Jin and Mei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chao Mei, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.